ASH 2022 | Choosing between continuous and time-limited therapy in patients with high-risk CLL
Adam Kittai, MD, Ohio State University, Columbus, OH, comments on the prognostic value of different adverse prognostic features in patients with chronic lymphocytic leukemia (CLL) treated with continuous therapy with a BTK inhibitor versus time-limited therapy with venetoclax and obinutuzumab. Dr Kittai explains that while data suggests that continuous therapy appears to be associated with better outcomes in high-risk patients, the patient’s preference should be taken into account when selecting a treatment. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
Explore our dedicated feature on genomic testing in CLL here: http://bit.ly/403y417
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Abbvie: Consultancy; Astrazeneca: Consultancy, Research Funding; Beigene: Consultancy; Janssen: Consultancy.
